With more than 25 years of experience, Rules-Based Medicine, a Q² Solutions company develops, validates and manufactures its assays with integrity and commitment for the most reliable, reproducible and highest quality assays. RBM is a leader in multiplex assay development, from with cytokines and chemokines to new clinical and disease-relevant biomarkers. RBM’s assay development includes an initial singleplex, then multiplexing, proprietary blocking buffers, as well as established standards and quality controls.

Complete the form to access this whitepaper.